YBX1 and cancer: This difference could be due to (i) the dosage effect of Ybx1 from complete genetic depletion in our study versus partial depletion by small interfering RNAs in other studies; (ii) varying activities of Ybx1 in different cell types; and (iii) developmental or pathological contexts of NPCs vs. cancer cells.